A Clinical Study of PA5 in Patients With Advanced Solid Tumors

Recruiting now · Phase 1

Conditions studied: Advanced Solid Tumors, Cancer

In brief

The goal of this clinical trial is to learn if PA5 is safe and works to treat advanced solid tumors in adults. It will also learn about the tolerability and PK/PD profile of PA5. The main questions it aims to answer are: * Is intravenous infusion of PA5 monotherapy safe and tolerable for patients with advanced/metastatic solid tumors? * What is the maximum tolerated dose (MTD) and recommended dose for Phase II clinical trials (RP2D) of PA5 monotherapy? In the escalation phase, participants will receive PA5 via intravenous infusion on Day 1 of Cycle 1 (28-day cycle). If no dose-limiting toxicity (DLT) occurs, treatment continues from Cycle 2 onward with adjusted frequency (every 2-4 weeks). In the expansion phase, participants will receive PA5 with the frequency determined based on the results of the escalation phase.

Key facts

Study ID

NCT07702162

Run by

Chongqing Peg-Bio Biopharm Co., Ltd.

People needed

49

Starts

2025-11-14

Expected to finish

2027-06-04

Last updated by the study team

2026-07-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years, male or female.
• Patients with histologically or cytologically confirmed advanced/metastatic solid tumors that are unresectable, stage III or IV, have failed standard therapy, are intolerant to standard therapy, have no standard therapy available, or unable to benefit from standard therapy.
• At least one evaluable lesion (dose escalation phase) or at least one measurable lesion (dose expansion phase) according to RECIST v1.1 criteria.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Expected life expectancy of at least 12 weeks.
• Brain metastases must be well-controlled and without epileptic symptoms.
• Participants must have adequate organ and bone marrow function.

You may not qualify if…

• Participants who have received chemotherapy, targeted therapy, anti-tumor Chinese herbal medicine, or palliative care within 2 weeks or 5 half-lives (whichever is longer) prior to the initiation of study treatment; or major surgery, radiotherapy, immunotherapy, or participation in another clinical trial within 4 weeks or 5 half-lives (whichever is longer); or live virus vaccination within 4 weeks or inactivated vaccination within 2 weeks prior to initiation of study treatment.
• Presence of pleural effusion or ascites requiring clinical intervention (except for participants not requiring drainage or with stable effusion for ≥2 weeks after drainage); presence of pericardial effusion (except for minimal, stable effusion for ≥2 weeks).
• Toxicities from prior anti-tumor therapy have not recovered to ≤ Grade 2 per NCI-CTCAE v5.0 (excluding toxicities judged by the investigator to pose no safety risk, such as alopecia).
• Participants taking drugs known to prolong the QTc interval or with risk factors for QTc interval prolongation.
• Clinically significant active bacterial, fungal, or viral infection.
• Other malignancies besides the indication under study, either currently or in the past, except for: cured cervical carcinoma in situ (stage IB or lower), non-invasive basal cell or squamous cell skin cancer, malignant melanoma with complete remission (CR) >10 years, or other malignancies with CR >5 years.
• Pregnant or breastfeeding women.
• History of allergy to polyethylene glycol compounds.
• Prior treatment with ADI-PEG20 or other drugs of the same class.
• The investigator believes the subject is unsuitable for participating in this clinical study.

Where it is running

• Fujian Cancer Hospital — Fuzhou, Fujian, China (enrolling)
• Fudan University Shanghai Cancer Center — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.